Skip Navigation or Skip to Content

MES

Data Fabric In the Lab R&D Space and In Biologics Manufacturing

How Pfizer Is Building a Scalable Data Fabric for R&D and Biologics Manufacturing

Unlock a behind-the-scenes look at how Pfizer is harmonizing data across R&D labs, quality systems, and biologics manufacturing using a modern Data Fabric architecture.

This webinar gives biopharma leaders a practical blueprint to eliminate data silos, accelerate tech transfer, and prepare their operations for MES modernization and AI adoption.

Watch the Webinar Replay

Learn directly from Pfizer’s Digital Manufacturing & Data Technology teams, together with Zaether’s industry experts.

What You Will Learn in This Webinar

A practical, real-world look at Pfizer’s Data Fabric

  • How Pfizer designed a harmonized data layer across R&D and Biologics Manufacturing.
  • How Data Fabric enables faster decision-making and reduces manual handoffs.
  • Pfizer’s approach to integrating MES, LIMS, ELN, historians, and cloud analytics.

A clear roadmap you can apply immediately

  • Steps to begin your own Data Fabric initiative without a full platform overhaul
  • The link between Data Fabric, MES modernization, digital tech transfer, and AI
  • Common pitfalls that slow adoption across sites — and how to avoid them

Lessons from Pfizer’s digital transformation

  • Architecture patterns that scale globally
  • How to build cross-functional alignment between IT, MSAT, QA/QC, and R&D
  • What success looks like for biologics, CGT, and high-throughput labs

Why Biopharma Is Moving Toward Data Fabric

A modern Data Fabric creates a unified, contextualized source of truth — enabling:

  • Faster batch release
  • More efficient tech transfer
  • Real-time visibility for QA/QC
  • Automated data flows into MES and cloud analytics
  • A reliable foundation for AI and predictive modeling

If your organization struggles with system fragmentation, slow data access, or integration challenges across R&D and manufacturing, this webinar shows exactly how leaders like Pfizer are solving it.

Featured Speakers

Taylor Wagner
Digital Manufacturing & Data Technology
Pfizer

Darshak Shah
Principal Digital, Data & Analytics Engineer
Zaether

Who Should Watch This Webinar

This session is ideal for:

  • CIOs & Digital Transformation Executives
  • IT Directors & Data Architects
  • MSAT, Digital Manufacturing, and Operational Excellence teams
  • QA/QC digital leaders and data integrity owners
  • R&D Informatics, Lab Automation, and Data Strategy leads
  • Anyone responsible for MES, LIMS, ELN, UNS, Data Platforms, or AI initiatives

About Zaether (part of Stellix)

Guiding Biopharma to Digital Excellence with Proven Expertise and Tailored Solutions.
We aim to empower Biopharma companies by providing specialized IT consulting and implementation services. With over 60 years of IT/OT experience in the life science industry, we simplify digital integration, optimize data management, and streamline operations to ensure compliance and innovation.

We work with innovators like Pfizer, Spark Therapeutics, Gilead, Lonza, and Moderna.

Related Resources

MES
Unlocking the power of MES in Bioprocessing
Access free Webinar with Tim Adkins. Discover how integrating Digital Tech Transfer into an MES strategy can streamline manufacturing processes and enhance compliance with bioprocessing.
Read more »
Tech Transfer
Optimized Digital Tech Transfer Strategy and Roadmap
Explore a detailed breakdown of how to develop digitally enabled process and product knowledge transfer between process development and manufacturing.
Read more »
Tech Transfer
Unleash Biopharma Innovation with Proven Digital Strategies
This eBook uncovers six critical strategies to harness digital transformation in biopharma, helping your organization streamline operations, leverage data, and enhance collaboration. Learn from industry leaders and see real-world examples of success.
Read more »
UNS
Life Sciences Giant Teams with ZAETHER to Implement UNS
In 2019, a Fortune 500 diversified life sciences company opened a $90 million facility built to manufacture viral vector gene therapies for its biotech customers. Determined to make it a state-of-the-art facility, the company’s leaders saw an opportunity to reengineer its existing data management approach.
Read more »
« Back to Insights